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Abstract 
Many obstacles impede the success of biotechnology startups. The Food and Drug 
Administration's (FDA) clinical trials is one of the primary challenges. The FDA currently 
imposes rigorous standards before a biotechnology company’s product is approved for 
dissemination to the public. A result of FDA standards is a costly 7.5-year average product 
development pipeline that hinders companies, already limited in cash and resources, from 
quickly generating steady streams of income to sustain their businesses. After a literature review, 
several important areas of focus were highlighted by individuals who successfully started 
biotechnology companies or have expertise in the area. They advocated best-practice policies in 
areas for securing funding, navigating the FDA’s clinical trials, utilizing local resources, and 
testing products. In addition, a case study was conducted on a Texas-based biotechnology 
company called Mirna Therapeutics Inc., to highlight some of the best-practices endorsed from 
literature, as well as to show their limitations. This research could potentially foster a new way of 
looking at biotechnology startups and provide insightful techniques which entrepreneurs could 
utilize for their current or future businesses in the field. 
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Introduction 
With the rise in the number of startups across the U.S., it is little wonder that this 
expansion has reached the healthcare industry as well. Naturally, many people equate startups 
with small businesses or corporations. However, in reality, startups have unique attributes that 
differentiate themselves from small businesses and corporations. They are also comprised of 
individuals seeking to create new value with scarce resources in high-risk situations. Startups 
working with biotechnology have additional high-risks associated with them since they work 
with the human body. However, they offer innovation, job growth, and a reduction of healthcare 
costs. Their biggest problem is the ability to transition from an idea to a startup and finally to a 
sustainable business. In order to do so, biotechnology startups must face multiple obstacles such 
as raising money to do research and development, conducting numerous lab testing, and passing 
the Food and Drug Administration’s stringent clinical trials by performing human subject testing 
before marketing their product.  
This thesis will be discussing the issues surrounding fledgling biotechnology startups and 
how these seemingly insurmountable obstacles lead many medical entrepreneurs to fail in their 
attempts to create a sustainable business. A literature review on the subject will be presented 
from those whom have succeeded in creating biotechnology companies to shed light on the best-
practices advised by experts in the field. These best-practice protocols will be applied to the 
Austin Texas based company, Mirna Therapeutics Inc., to not only highlight their merit but also 
showcase their limitations.  
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The Formation, Logistic, and Importance of Startups 
The line between a startup and a small business or corporation can become blurred; both 
have few employees and are for-profit. Upon closer inspection, startups have unique attributes to 
their nature. Startups differ in the characteristics of the people working in them and the nature of 
their business models. Academics have defined startups as a group of individuals who are trying 
to create new value with scarce resources in high-risk situations (Beverley). These individuals 
engage in entrepreneurship, a creative destruction process of new goods and services, markets, 
improved production processes, and organizational structures, leading to competitive barriers and 
economic profit (Montanye 7). Entrepreneurs in a startup are also seen as individuals who 
specialize in taking “judgmental decisions about the coordination of scarce resources while 
engaging in creative destruction” (Casson 19-20). They see a need to be filled in the market and 
take the risk of creating something to meet that void (Beverley). Usually, the formation of such a 
group is due to the recognition of a problem, whether personal or societal, in the market place 
that they believe can and need to be addressed by them.  
The second difference between the two business entities is in their predictability. 
Whereas traditional small business owners and corporations have businesses which are usually 
run with relatively smaller risks and a constant, steady stream of revenue, startup founders are 
operating with little ability to see where their next source of revenue will be coming from. The 
business model of a startup is starkly different from others. Most academics would agree that 
startup is a phase of the future business or a “temporary organization used to search for a 
repeatable and scalable business model” (Blank). A startup is not an ongoing business that lasts 
for years, rather, it is a stage in which the business either attempts to “grow up” and become a 
company or fails to do so and dies (Beverley). It attempts to “grow up” in risky and not well 
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understood market conditions. During this phase, it tries to establish a business model or strategy 
to stabilize its source of revenue and continues to find ways to scale the business. However, 
because of the limited resources at the startup’s disposal, many will fail and die before becoming 
companies.  
 Many startups fail because of their inability to secure capital or funding from investors 
(Tsai and Erikson 49). If it cannot secure funding, the startup will not be able to acquire initial 
adopters or early customers to test their product or service. Some may not have the funds to even 
produce their idea. However, sometimes a startup does not fail due to their inability to secure 
initial funding, but rather on the basis of what their future company is premised upon or what 
hypotheses are made about the business.  
Many startups have adopted a lean approach by becoming what are called “lean startups.” 
These companies minimize their initial need for capital by manufacturing their idea or service in 
the most efficient and crude way possible in the hopes of putting their idea out into the market as 
fast as possible (Ries 45). These startups are built upon three guiding principles or hypotheses 
that dictate the foundations of their business. These hypotheses include problem, value, and 
growth (Ries 64). When these hypotheses are not validated by the entrepreneurs, their entire 
startup business could falter and subsume substantial losses in time and resources, which could 
ultimately lead to failure.  
The problem hypothesis is the assumption entrepreneurs have that there is a problem in 
the market place, also known as its market niche, in which the startup will fill. The problem is 
usually from their potential customers. Entrepreneurs in lean startups are advised to reach out to 
their potential customers for their business models and solicit information firsthand by asking if 
the assumed problem exists. If the consumers do have a problem, then the entrepreneurs are said 
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to have validated their problem hypothesis for their business. Many startup founders neglect the 
importance of asking their potential customers if they actually have the problem. Entrepreneurs 
can potentially become engrossed in the process of creating a service or product that looks 
polished and refined but does not actually solve the problem or there was no problem in the first 
place. This leads to the production of unnecessary features and, in the worst case, an unwanted 
product. Because of the time, money, and energy placed into producing such a product or 
service, the startup may not have the necessary resources in their already scarce arsenal to 
survive through the loss. Morale would also be low, leading to higher tensions and potential 
failure of the fledgling startup.  
The second hypothesis is the value hypothesis. In this hypothesis, entrepreneurs are now 
positing that the problem they have identified actually has value in it, meaning the customers or 
consumers with the problem are actually willing to pay for their problem to be solved by the 
entrepreneurs. Similar to the first hypothesis, entrepreneurs who do not validate this hypothesis 
will accrue heavy losses by producing a product or service that consumers will not necessarily 
pay for. With no streams of revenue to support or keep the startup afloat, it will quickly fail. As 
one professor with experience in multiple startups puts it, “cash is king” and the blood or life 
support of a startup (Beverley). Validation of the second hypothesis is a bit trickier than the first. 
Customers who say they will pay for the startup’s service or product upfront may not actually 
pay when the product or service is delivered to them. Rather, they may be reluctant to pull out 
their wallets. One way to offset this, which many lean startups have begun testing, is the use of 
an MVP or minimal viable product (Ries 96). The MVP is the most basic form of the idea with 
little features and add-ons, thus requiring the least amount of resource, energy, and time to build. 
Entrepreneurs then target their MVP at their potential customers and observe whether or not they 
7 
 
are willing to purchase the MVP while collecting consumer feedback. Based on the feedback 
collected, entrepreneurs use the information they learned, called validated learning, to iterate on 
or modify their MVP and create the product or service that the customers actually want and are 
willing to pay for (Ries 99).  
The final hypothesis, the growth hypothesis, hinges upon the continual iteration of the 
MVP by entrepreneurs. During this process, entrepreneurs are constantly looking for ways to 
acquire more customers and grow their customer base. In this hypothesis, the founders are testing 
and validating which engine of growth will allow their startup to accelerate the most in size. 
Without finding a suitable engine of growth for the startup, the business model is not scalable. 
These engines of growth can either be sticky, meaning it has low attrition rates, viral, word-of-
mouth, or a few others. For example, the viral engine of growth is built on the premise that the 
product or service will become very attractive to potential customers based on its popularity with 
initial adopters. This will potentially lead to streams of people who will flock to use the new 
product or service. The exponential growth of tech companies, like Facebook, highlight the 
growth ability of the viral engine. Once the company has successfully achieved and sustained 
growth and revenue, it is usually no longer called a startup (Hall).  
Startups also play a large, important role in the economy. Entrepreneurs create wealth 
through new services or products which foster economic growth through their startup companies 
(Kolympiris 227). These startups help generate economic growth by creating more jobs in the 
economy, accounting for up to 50% of new jobs created in 2016 (Fetsch). In addition, startups 
provide new services and products to the public that meet needs and improve quality of life while 
generating huge amounts of revenue. As a result, they also bring in tax revenue for the local area 
since companies are obligated to pay taxes. For example, the Austin Technology Incubator (ATI) 
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was able to produce more than $20 million in local tax revenue from 2003 to 2012 (UT News). 
At the same time, the incubator, a workplace for startup companies, was able to generate $880 
million in economic output and created 6,520 jobs in the area. In 2015, due to the rising number 
of startups located in Austin, the number of dollars invested in Austin was $911.3 million. The 
number of incubators, institutions which provide the infrastructures, people, and resources for 
entrepreneurs to get started, have increased to 46 (Austin Chamber of Commerce). While many 
of these benefits are relevant to almost all startup companies, biotechnology startup companies 
have a few extra benefits and disadvantages that are unique to them—the topic of the next 
section.  
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The Biotech Company  
A. An Overview of a biotechnology company  
In general, biotechnology startup companies are very similar to other startups. They 
address a need in the market. However, as the name implies, their market focuses specifically in 
healthcare and medicine. Startups working with biotechnology deal with high-risks due to the 
inherent challenges of working with the human body (Tsai and Erickson 50). These companies 
try to develop new solutions to tackle health issues or provide novel technologies to expedite 
treatment and efficiency within the healthcare system. In theory, the benefits these startups 
provide to the economy are tremendous, as they stir innovation, create new jobs, and reduce 
healthcare costs. 
While the problem and value hypotheses are evident, as there are a multitude of problems 
in healthcare currently and huge amounts being spent in the industry, the hardest one is 
sustainable growth (Grohn 67). In order to transition into a sustainable business, the startup must 
pass the FDA clinical trials, an extensive quality check on their product, before it is released into 
the public for use.  
Once a biotechnology company starts growing, the amount of benefits it generates 
include: economic growth, local revenue, goods and services for the public, new jobs and wealth, 
and many others.  
B. Exclusive Benefits from Biotechnology Companies  
One important aspect of startup biotechnology companies is their ability to reduce 
healthcare costs in a number of ways. Entrepreneurs, by their nature, look for new, creative 
solutions to existing problems. They help tackle existing issues of healthcare such as rising cost 
10 
 
of care with innovative solutions (Brenner 28). With a national annual expenditure of over one 
trillion dollars and one of the lowest health outcomes across Western countries, the U.S. has an 
extremely poor rate of return from their healthcare spending (Bodeneimer and Grumbach 143) 
(Davis et al. 7). Currently, healthcare is not sustainable and still operates with outdated 
technologies such as paper records and old equipment (Chowdhury 32). Top-down methods by 
the government and corporations have failed to provide newer, digital technologies to help 
modernize healthcare (Chowdhury 31). New biotechnology companies could step in and meet 
the demand for quicker and efficient solutions by delivering better quality healthcare at a lower 
price with their solutions. These startup companies invent methods to reduce the costs to develop 
their MVPs, thus giving the public solutions which cost less than the ones in the status quo. An 
example is the lean startup, Inchor Therapeutics Inc., which developed a novel way of working 
with stem cell technologies in an affordable laboratory to combat age-related diseases (Grohn 
62).  
 Another important aspect that biotechnology companies provide is the increased sense of 
control for consumers in the healthcare industry (Sage). New technologies developed by these 
companies would provide more and better options for consumers to take control of their own 
health while limiting the need for physician visits. For example, biotechnology companies which 
develop digital or mobile medical applications allow consumers to run diagnostics with Do-It-
Yourself (DIY) technologies. One biotechnology called WellDoc uses an FDA-cleared, 
physician-prescribed, and reimbursed digital medicine product called BlueStar (Steinberg 915). 
BlueStar is a software application which can be accessed on a mobile device and aids diabetic 
patients in monitoring and managing their blood glucose levels (Steinberg 915). There are many 
other companies which have created DIY technologies for the consumer to monitor their 
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biomarkers and generate feedback. Other groundbreaking mobile health applications include an 
iPhone-powered electrocardiogram (Fellay 1). Not only do these devices empower the consumer 
by allowing them to do some of the easier medical tasks themselves, but they also reduce 
healthcare costs with fewer visits, provide greater data accessibility, and up-to-date information 
(Fellay 1). While these benefits are certainly welcoming for the economy and the general public, 
biotechnology startup companies face many challenges before their innovative solutions hit the 
general public and markets. Some of these obstacles are ones which startups in other industries 
face, while some are unique to startups operating in healthcare.  
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Issues Surrounding Biotechnology Startups and Best-Practices from Literature 
 Many of the problems faced by biotechnology startups are the same ones startups in other 
industries face. These include obtaining funding capital, management of human resources, and 
public relations. Furthermore, biotechnology companies have a whole host of issues exclusive to 
them. One such issue is the regulatory frameworks set by the FDA (i.e. clinical trials). These are 
long, expensive, and have low success rates (Rose). Another problem is of location for a 
biotechnology startup. Without the availability of wet labs or the scientific experts within their 
location, biotechnology companies will have a hard time flourishing (Kolympiris 228). Issues in 
regards to the product or service such as: research and development, manufacturing, sales and 
marketing strategy, are all areas the company has to solve before it generates even its first stream 
of revenue (Durai 6). This highlights the necessity for management to cautiously manage the 
changes a biotechnology company must go through from the startup growth phase to a company 
(Rafferty 479). Each of these issues will be discussed in more detail in the following sections.  
I. Biotechnology Startup Issues 
A. Capital Funding  
All startup companies require funding to begin, either for acquiring new customers or for 
developing their MVP. Biotechnology companies are no different. However, venture capitalists 
(VCs) and angel investors, groups and individuals who invest in startup companies respectively, 
have invested more in other industries such as technology platforms than biotech. Numbers 
dating to 2005 indicate VCs have invested only $300 million versus $20 billion into other 
technology platforms (Moran). Furthermore, securing funding from VCs is much harder for a 
biotechnology than a technology company due to the science and risks involved, such as working 
with the human body (Durai 7). However, a recent report has shown a significant increase in the 
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past decade in capital investment into biotech. In 2015, $71 billion was invested, a record high 
(EY 4). However, the report indicated several signs of a slowdown such as decelerated funding 
in every category and a lack of initial public offerings (IPOs) (EY 5). An IPO is when a company 
goes public to collect public funding to continue their strong business. The lack of investment 
may be due to researchers' incomplete understanding of the sciences involved in biotechnology 
companies, such as those working on developing new drugs and treatments and the failure to 
pass FDA clinical trials to gain approval (Moran). Some biotechnology companies, such as 
WellDoc, require less capital since their product incorporates more digital technology rather than 
the synthesis of new biological drugs and treatments. Thus, they do not need to undergo the FDA 
clinical trials, lessening their financial burdens and increasing their chance of success.  
The lack of complete scientific knowledge in biotechnology companies that are 
developing new drug therapies carries high risks for investors because of the uncertainty on 
where the intellectual property will go (Moran). In other words, there is a high probability the 
company’s proposed solution of a therapy or drug may not pan out as they allegedly expected it 
would when they tried to raise capital from VCs and angel investors. This lack of confidence in 
the startup decreases its chances of securing funding for its venture. No money or capital equals 
no product or business. Unfortunately, the initial round of funding called the “seed round” is the 
riskiest because the biotechnology company has only just began developing their idea (Durai 7). 
Seed investment represented only 0.03% of venture capital funds around the mid 2000’s for 
biotech companies working on drugs and therapies (Durai 7). A significant worry is that low 
seed funding may stifle biotech innovation.  
One of the highest barriers to entry for a biotechnology company startup is the significant 
amount of cost in procuring a basic laboratory to begin research and development. Historically, 
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the acquisition and maintenance costs of equipment have been prohibitive (Grohn 61). Without 
the initial seed funding, biotechnology companies face a roadblock in simply getting started. 
However, once they do, additional issues subsequently arise to challenge the fledgling company.  
B. FDA Regulatory Frameworks 
I. Drugs 
As mentioned earlier, the most notable obstacle is the FDA guidelines and policies for 
biotechnology companies. Pharmaceutical active ingredients, biological items such as tissues or 
cells, and any invasive medical treatment therapies are classified as drugs under FDA's statutory 
definitions (FDA, “Conducting Clinical Trials”). This indicates these products must undergo 
clinic trials to test the safety and efficacy against a placebo and the current standard of treatment 
in a double-blind test with a sufficiently large patient pool.  
Before the procedure or drug is tested on a human population, a preclinical study phase is 
conducted in the lab on animal test subjects. The animal and laboratory studies phase usually 
takes about 4.5 years (MD Anderson). Afterwards, the treatment is then moved to Phase I of the 
FDA clinical trials where it is tested for safety, dosage, proper administration of treatment, and 
initial response to the treatment in fewer than 100 healthy volunteers or patients with the disease 
for several months (MD Anderson) (FDA, “Step 3: Clinical Research”). On average, the FDA 
lists about 70% of drugs or treatments moving to the next phase, Phase II (FDA, “Step 3: 
Clinical Research”). Phase I is generally for monitoring the treatment or the drug’s interaction 
with the human body (FDA, “Step 3: Clinical Research”). Phase II tests up to several hundred 
patients from several months to two years on the efficacy and the potential side effects from the 
treatment (FDA, “Step 3: Clinical Research”). 33% of treatments move to the next phase (FDA, 
“Step 3: Clinical Research”). Phase II provides additional safety information from patients. In 
15 
 
Phase III, the treatment or drug testing recruits roughly 300 to 3000 patients with the illness. The 
test is conducted for a length of one to four years. Phase III provides the most data on clinical 
safety and efficacy. It tests whether the new treatment is more effective than the standard and 
reveals any uncommon or long-term side effects in patients. Generally, only 25-30% of the drugs 
and treatments move on to the next phase (FDA, “Step 3: Clinical Research”). At this stage, the 
FDA collects all the data received from the first three clinical trials and evaluates the safety and 
efficacy of the treatment before it decides whether or not to approve it (MD Anderson). The 
fourth and final clinical trial, Phase IV, tests already approved FDA treatments to gather more 
information on long-term effects in several thousands of volunteer patients (FDA, “Step 3: 
Clinical Research”) (MD Anderson).  Each of these stages can last anywhere from a few months 
to a few years, with the total average to be about 7.5 years (Sertkaya). Preclinical research by 
itself can take many years before it is deemed favorable enough to undergo clinical trials. This 
makes the total amount of time from discovery to approval by the FDA to be between 10 to 15 
years for a typical drug (Sertkaya). For example, the Texas-based Mirna Therapuetics company 
spent roughly five years on preclinical research before being ready to undergo clinical trials 
(David Brown). The stages themselves, when combined, can last anywhere from five years to ten 
years (FDA, “Step 3: Clinical Research”).   
In addition to a substantial amount of time invested in the trials, a significant amount of 
capital is also necessary to go through the trials. An estimate of between $161 million and $2 
billion is required to bring a new drug to market, with the bulk of the cost being from phases two 
and three due to greater patient volume and time needed (Sertkaya). The biotechnology startups 
face tremendous difficulty in procuring the necessary funds to pay for the compliance costs of 
running large FDA clinical trials to test their products or treatments (Epstein). 
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II. Devices 
The FDA’s policies for regulating medical devices are different than biologicals. Overall, 
they are much shorter and less expensive. The FDA’s categorization of medical devices is large. 
It includes applications that offer medical reminders, provide information about drug 
interactions, use Global Positioning System to alert potential dangers, equipment for surgery, 
diagnosis, and treatment (Fellay 4). Medical devices and applications are separated into three 
groups based on their risks to the user. Class I devices pose little threat to users if they 
malfunction and are therefore subject to the most limited set of regulations (Fellay 4). If the 
device is similar to a device currently on the market, it will be cleared for marketing. Some Class 
I devices may need a 510(k) premarket notification. The 510(k) premarket notification is a letter 
which compares the proposed device to ones in the market and tests performance (Faris 4). Class 
II devices are almost always subject to a need for 510(k) premarket notification to the FDA with 
around 10-15% requiring clinical data to support its performance and safety (Faris 4). These 
devices have the potential to result in a mild to medium injury in cases of malfunction (Fellay 5). 
They also have special controls by the FDA (Faris 3). Finally, Class III medical devices are ones 
which could result in death or serious injury in the case of malfunction. These devices must 
obtain FDA premarket approval similar to a biological drug instead of just a premarket clearance 
(Fellay 5). Much of the steps for a Class III device is similar to drug development but the path to 
approval by the FDA is not through four clinical trials but through an investigational device 
exemption for premarket approval (FDA, “The Device Development Process”). It is almost 
synonymous to a Phase III clinical trial for a drug. The data is then aggregated for FDA review 
and approval. The process usually takes a few years and can be anywhere from $1 million to $10 
million (Fellay 2) (Hogan).  
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As these numbers and the 7.5-year timeline show, the process to become FDA approved 
is long and time consuming. Much can go wrong within the timeframe. To avoid potential delays 
in the process and further downstream costs, medical entrepreneurs must learn to navigate 
through these regulatory frameworks. Otherwise, a failure to understand and comply with 
regulations will scare away potential venture capitalists, angel investors, or partners (Rose).  
C. Product Testing  
In addition to the regulatory frameworks and funding requirements, there is the actual 
matter of the testing itself. There is the issue of test site selection, as in where the test will be 
conducted and where patients will go to be part of the clinical trial, and the need for recruitment 
of medical personnel to handle and administer the drug or device being tested (Deb 5). Delays in 
either part can significantly increase the time-to-market. In addition, a patient pool must be 
assembled and the patients’ medical data must adhere to clinical trial protocols by the FDA and 
be coherent for interpretation (Deb 6). Conventional clinical processes require extensive 
monitoring, creating lag time between data gathering and analysis (i.e. physicians receiving the 
results from exams at a much later date). This could potential cause a delay in profitability and 
incurring further regulatory sanctions from the FDA.  
II. Best-practices and Potential Solutions from Literature 
D. Startup Environment  
The location of a biotechnology startup company for initial operation is a very crucial 
decision in its business plan. As mentioned earlier, initial biotech startups require seed capital for 
basic laboratory equipment to develop their product as well as experts to help them navigate the 
intricate, maze-like regulations of the industry from the FDA. Therefore, the location selection 
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must consider both the personal characteristics of the entrepreneur or entrepreneurs and the 
environmental factors which can potentially play a role in the success of the company 
(Kolympiris 228). A study followed 187 venture-capital backed biopharmaceutical firms that 
were started by 275 entrepreneurs in the U.S. Using an empirical model developed in the study, 
researchers were able to show certain patterns in the decisions these entrepreneurs made when 
deciding where to start their companies (Kolympiris 233). The research indicated the proximity 
to knowledge assets, such as a medical school, hospital system, universities as well as access to 
capital, from venture capital firms or large pharmaceutical companies, were important factors in 
the entrepreneurs' decisions on where to begin their startups.  
One of the critical factors for selecting a location to start is the startup’s proximity to 
resources, such as capital, to help it get started. As already mentioned, unlike software 
technology companies, biotechnology companies require large overhead expenses to produce a 
minimum viable product to even begin testing in the FDA's clinical trials (Steinberg 914). 
Entrepreneurs should, and usually do, have a high probability of picking a location where there's 
a venture capital firm nearby, as mentioned in the Kolympiris study. Aside from capital, 
biotechnology companies require specific equipment, such as quality lab space to develop and 
test their products when conducting preclinical animal experiments. Biotechnology companies 
may have to relocate to different areas in order to acquire sufficient space to either retrofit it into 
a wet lab workspace or rent out wet lab space from pharmaceutical companies, hospitals, or 
medical schools (Kirkpatrick 130). Therefore, proximity to existing healthcare or medical 
infrastructures and organization is beneficial when attempting to acquire lab equipment and start 
a biotech company.  
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Another key component in the decision on location is the knowledge assets within a 
location. Since biotechnology founders have to be familiar with the regulations and guidelines 
within their industry from the FDA, it would be wise to not only know who the large players are 
in the field, but to also make an effort to collaborate with them (Lorenzetti). Large players in the 
field of healthcare are pharmaceutical companies, hospital organizations, and the FDA. One 
unique, initiative model is the collaboration between the pharmaceutical industry with small life 
science biotech companies (Styhre and Remneland-Wikhamn 256). The small firm can capitalize 
on the mature pharmaceutical company's expertise, their capital resources such as labs, 
equipment, funding, in exchange for a share of the potential profits and sometimes intellectual 
property rights. Industry experts from mature pharmaceutical companies would be extremely 
beneficial to startups to help in navigating the complex and lengthy clinical trials, saving time 
and money by avoiding mishaps. Medical schools and hospital organizations could also serve 
similar functions for a biotech startup company. For example, the University of Texas Health 
Science Center in Houston has a fully functional wet lab space, limited used equipment (e.g. 
refrigerators, freezers, biohazard hoods, incubators, and centrifuges), and a suite of offices with 
furniture to help companies get started (Kirkpatrick 130). In addition, the Austin Technology 
Incubator recently partnered with Austin Community College to launch a startup business 
mentoring service with state-of-the-art biotechnology equipment, specialized wet lab space, 
conferencing areas, and an expert staff (IC2 Institute).  
E. Staffing, Management and Employment 
Similar to all businesses, biotechnology companies face challenges in accessing adequate 
capital, managing limited resources, handling partnerships, ability to make wise go or no-go 
complex decisions, and correctly making appropriate risk assessments in a realm of uncertainty. 
20 
 
One of the pivotal moments in a biotechnology company is the transition from the research 
discovery phase, when the initial discovery of a new drug, technique, or equipment was made, to 
product development and safety testing (Rafferty 480). Thus, priorities and objectives change 
from getting the science down to making the product viable for testing and being effective and 
safe. This requires a need for new skills and talent. There may be an increase in hiring and rapid 
expansion of staff and the purchase of new infrastructures to accommodate the new needs.  
Research has shown that company leaders should be open in communication about 
changes and what to expect in transitions. Individuals and teams are advised to be patient during 
decision making times and seek information to understand the changes that are happening 
(Rafferty 479). Much of the burden of running the biotechnology company in its early stages fall 
on the founders or upper management, as they strategically plan for the company. For example, 
management has to decide whether to build, license, or sell their idea and scientific research 
(Tsai and Erickson 50). At times, all three may come into play depending on the environmental 
factors of the industry. Management must also decide if it is favorable to seek a corporate 
alliance with large pharmaceutical companies when times are tough and capital is low. Strategic 
alliances could help salvage a biotechnology startup when faced with difficulties from clinical 
trials. Other tasks of equal importance include generating and maintaining free cash flow, 
planning and executing a viable financing strategy to fund daily operations and research and 
development, and securing intellectual property rights on their scientific research (Tsai and 
Erickson 53). These all must be managed and dealt with to maintain the company and have a 
successful run in the FDA's clinical trials. Therefore, it is imperative that the leaders of the 
company are seasoned managers with vision and business acumen in dealing with high-risks and 
many difficult challenges.  
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F. Technology  
In order to conduct an accurate and successful clinical trial, the sponsor or biotech 
company conducting the trials must assemble an adequate patient pool to test their new product 
on (Deb 7). The public health data in internal databases, such as from the U.S. Centers for 
Disease Control and Prevention, can be used to select locations with adequate patients of the 
right condition to test. Large hospital networks or those who cater towards specific patient 
groups could also be potential areas of test sites.  
Finally, the use of technology can drive this process more quickly and smoothly. With the 
advent of many technological innovations, biotech entrepreneurs can leverage such advantages in 
their tests. For example, sponsors can implement a centralized control mechanism and a cloud-
based platform to regulate quality control and access and retrieve information readily instead of 
using paper (Deb 7). This would speed up communication between teams and reduce human 
errors during the trials. A digital platform can further help in streamlining data collection such as 
the Electronic Data Capture (EDC) system which can upload information to the cloud platform 
and be readily available in real-time. This aggregated pool of data from the study can then be 
analyzed and generated into reports by either data analysts or the use of machine learning 
algorithms.  
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Case Study on Mirna Therapeutics Inc.  
 In the subsequent sections, research findings on Mirna Therapeutics Inc. will be 
presented to assess the biotechnology company’s strategy and success in navigating through the 
challenges listed above. It should be noted that not every company will face all of the problems 
listed above and certain information on the companies will be limited due to the scarcity of 
literature on company decisions and information that are usually reserved for the board of 
directors or leadership of the company. Nevertheless, in the following sections, an attempt to 
extrapolate and assess how well the company’s strategy embodied the best-practices from 
literature mentioned earlier will be made, and whether the practices were able to help 
circumnavigate the issues which plague biotechnology companies.  
 
History and Background  
 Mirna Therapeutics Inc. was founded in Austin by Dr. Matthew Winkler, who first 
founded Ambion in Austin Texas (Stoudemire). Ambion synthesized chemical reagents and tools 
that were used to work with oligonucleotides and RNA-related research applications (Thermo 
Fisher Scientific). Dr. Winkler was very successful with his initial company, Ambion, and later 
sold it for $300 million (Stoudemire). Eventually, he used a portion of his money to start another 
company in Austin called Asuragen Inc., which developed diagnostic kits for cancer, genetic 
diseases, and generated a lot of information on the potential therapeutic value of 
oligonucleotides, specifically micro-RNA. Over the years, the company developed a portfolio of 
micro-RNAs and their potential clinical use. Dr. Winkler used the information from the RNA 
portfolio and his personal resources to form a branch company called Mirna Therapeutics Inc.  
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The Science  
 The science behind Mirna Therapeutics Inc. is the novel method of using micro-RNAs as 
oligonucleotide-based therapies for cancer treatment. Oligonucleotides are short nucleic acid 
polymers used in research that are usually 13-25 nucleotides in length and designed to hybridize 
to DNA or RNA. These short oligonucleotide micro-RNAs are important in the regulatory 
network of cell development and function as individual micro-RNAs can control several hundred 
genes across multiple pathways (Brown). Micro-RNAs also function in cancer pathways as they 
are expressed inappropriately in tumors. The therapeutic application of oligonucleotides is these 
short fragments typically are comprised of nucleotide analogs that enhance the stability, delivery, 
tolerability, and/or potency of the drug candidate (Brown). They can also be used as drugs 
themselves under the label of so called siRNA-based drugs which act as antisense strands that 
bind to the sense strand of DNA (coding strand) to stop the production of certain proteins or 
activities that are causing the cancer.  
 The production of these short oligonucleotide strands is very simple. The sequence of the 
messenger RNA strand believed to be the cause of the disease can be referenced or searched in 
genome databanks. With the sequence information, the information can be inputted into a 
computer such as a GenFab Automated Gene Design machine or used in wet-lab methodologies 
such as polymerase chain reaction (PCR) mediated gene assembly to create the therapeutic 
oligonucleotides (Ellington). These strands are theoretically supposed to be highly specific due 
to the complementary base-pairing between nucleotides.  
 Despite their ease of manufacturing and high specificity, the biggest challenge 
oligonucleotide therapies face is delivery, getting the strands into the cells. They do not go 
through membranes easily due to size and therefore need to be encapsulated (Brown). High 
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concentrations of the strands are easily thrown out by the cell. Furthermore, the use of liposomes, 
a structural carrier made of lipids which encapsulates the strands, often accumulate in the liver, 
spleen, and bone marrow, affecting normal function and induces toxicity in patients (Brown). 
Sometimes these strands bind to inappropriate regions of the cell and trigger innate immune 
responses from the patient or affect the expression of other genes rather than the target.  
 
Funding  
 After the company first began in December 2007, it received seed funding of $3 million 
capital from its parent company, Asuragen Inc., in April 2008. While most startup companies 
don’t form from branching off of a parent company, Mirna Therapeutics Inc. was fortunate to be 
connected to Asuragen Inc., allowing it to receive immediate funding to begin its research and 
development of microRNA products.  
 With its advantageous location in Texas, Mirna was able to secure government funding 
from two different sources. In 2009, Mirna received a $5 million award from the Texas 
Emerging Technology Fund, created in 2005 by Governor Rick Perry to provide Texas with 
unparalleled advantages in research, development, and commercialization of emerging 
technologies here in Texas (Life Science Analytics 15). Following that year, Mirna was also able 
to secure $10.3 million dollars in funding from the Cancer Prevention and Research Institute of 
Texas (CPRIT) (Life Science Analytics 15) (Mirna, “Form 10-K” 4). The institute was 
established in 2007 with the goal to expedite innovation in cancer research and product 
development, giving better access to prevention based programs and methods across the state 
(CPRIT). The money received from CPRIT was essentially free money because the funding was 
non-deluded or “no strings attached” (Stoudemire).  
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 In some cases, government funding could potentially add uncertainty to a company’s 
research and commercialization due to requirements and limitations of actions placed on the 
company from the agency giving the federal or state grant (Mirna, “Form 10-K” 6). For instance, 
the powers given to the government could entail repayment of all the grant proceeds, termination 
agreements, claims rights, and other obligations. For Mirna’s case, their 10-K report, a 
comprehensive summary report of the company’s performance submitted annually to the U.S. 
Securities and Exchange Commission, indicates there were requirements to continue operating in 
Texas to prevent penalties. There was also the requirement to pay CPRIT less than 10% of a 
portion of their revenue from certain products until they met a certain portion of their grant 
money amount (Mirna, “Form 10-K” 4).  
 Aside from the money received from state grants, Dr. Matthew Winkler, the founder, also 
invested $36 million of his personal fortune, money he received when he sold his first company 
Ambion, into the company. In addition, the company went through multiple funding rounds with 
venture capital groups such as Pfizer venture, Baxter Ventures, and Sofinnova Ventures among 
the many others (Life Science Analytics 15) (Stoudemire). After raising funds from venture 
capitals, the company went on to launch an Initial Public Offering or IPO to raise money from 
the public by selling stocks or ownership of the company. On October 1, 2015, the Mirna 
Therapeutics Inc. offered 6,250,000 shares at a price of $7 to the public and generated 
approximately $43.8 million in proceeds. At the same time, it offered 2,395,010 private shares to 
CPRIT to raise an additional $16.8 million (Life Science Analytics 15). While Mirna went the 
route of financial fundraising like most startup companies, it was able to take advantage of its 
affiliation with its parent company, Asuragen Inc., and its location here in Texas to secure initial 
funding in its early days.  
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FDA Regulations and Clinical Testing 
 Mirna Therapeutics Inc. initially discovered their microRNA product, miR-34, in 2011 
and published its findings in scientific papers (Life Science Analytics 19). For the next couple of 
years, it continued to conduct research in animal models, such as mice, and published its findings 
in scientific journals. The product was tested in mice to inhibit cancer growth in lung, liver, and 
lymphatic system (Life Science Analytics 16). MicroRNA-34 serves as a master regulator in 
tumor or cancer suppression, thus a vital component in preventing the development of multiple 
types of cancers (Bader 1). In 2013, Mirna presented these preclinical data to a Keystone 
conference in Vancouver, Canada. The results were superb, as mice who were affected by late 
stage cancers showed significant signs of remission (Brown). Later that year, Mirna submitted its 
preclinical trial data to the FDA in order to begin conducting Phase I clinical trials on humans 
(Life Science Analytics 18).  
 Mirna outsourced its clinical trials testing to a CRO or contract research organization to 
offset costs and manufacture expenses for the MicroRNA product (Stoudemire). These 
organizations have all the necessary equipment, medical personnel, and resources to conduct 
clinical trials for biotechnology companies. The company began its Phase I clinical trial study by 
enrolling in a small number of patients that fit specific health requirements for the trial, such as 
having acceptable liver function based on vital sign measurements of bilirubin among other 
factors (Mirna, “A Multicenter Phase I Study of MRX34”). The trial recruited 25 patients in 
April 2014, which increased to 50 by November of that year, and 75 patients by July 2015 (Beg 
et al.). Before the trial was terminated early, it had a final enrollment of 155 patients (Mirna, “A 
Multicenter Phase I Study of MRX34”). The main focus of the trial was find the best dosage 
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amount for MicroRNA-34 for patients with liver cancer, lymphoma, melanoma, multiple 
myeloma, and renal cell carcinoma while minimizing the MicroRNA’s side effects (Mirna, “A 
Multicenter Phase I Study of MRX34”). Mirna’s clinical trial with MicroRNA marked the first 
of its kind (Life Science Analytics 18).  
 Dr. Jay Stoudemire, Vice President of Preclinical Development and Regulatory and 
Quality Assurance for the company, was in charge of managing the paperwork and regulations 
surrounding the clinical trials (Stoudemire). Dr. Stoudemire has 30 years of experience working 
with biotechnology companies, such as at Genetech and Xoma, and getting their products from 
the bench to the bedside (Stoudemire) (Mirna, “Mirna Board of Directors”). The medical aspect 
or the principal investigator for the clinical trial was led by Dr. Vincent O’Neill, the chief 
medical officer who has served on various other boards in other biotechnology companies 
(Mirna, “Mirna Board of Directors”). These highly experienced individuals were responsible for 
coordinating the clinical trials with the CRO. Dr. Stoudemire explained that each patient had 
several thousand pages of medical health data documentation. The data was maintained in a very 
controlled and regulated fashion (Stoudemire). Clinical research associates ensure documentation 
occurs at the CRO test sites. Every single clinical site must be approved with documentation and 
the final clinical study report with all the drug and patient data must be completed while 
precisely following the FDA’s guidelines and given to them. Dr. Stoudemire was in charge of the 
report. 
Another important component of the study which had to be constantly monitored by Dr. 
Stoudemire was the labeling and shipping conditions of the drug being tested. Every label made 
for the drug had to be accounted for in case of mishaps that could be life-threatening to the 
patient. The shipping conditions of the drug from manufacturing companies must ensure product 
28 
 
safety and quality until the time of use in the trials in order to prevent adverse effects. This 
aspect was also managed by the expert, Dr. Stoudemire. Therefore, having at least one expert on 
the leadership panel of a company to conduct clinical trials is extremely important and beneficial 
to help mitigate a plethora of possible complications, delays, and fines in the process.  
The dollar amount of the clinical trial was already high. Each patient’s total cost was 
roughly $65,000 (Stoudemire). Part of the reason for the high cost was because it was an 
oncology study and cancer is highly complex in nature. According to Dr. Stoudemire, additional 
costs include the $1 million for manufacturing the drugs for testing, the CRO contract of $10 
million, and the total cost was approximately $120 million dollars for an unsuccessful Phase I 
clinical trial with 155 patients. If the test was a phase II or III, with its larger patient sample and 
longer duration, it would have cost approximately $750 million.  
The study was unsuccessful because of unknown causes of high toxicity in patients 
taking the test drug miRNA-34. The study was halted by Mirna last year. This topic will be 
elaborated in the limitations section. 
 
Local Resources  
 Due to its connection with its parent company, Asuragen Inc., Mirna brought many 
scientists over to develop mircoRNA as a therapeutic agent for cancer (Stoudemire). It was a 
novel endeavor at the time, as there were no drugs that mimicked microRNA being tested.  
 The founder of Mirna, Dr. Winkler, is a resident of Austin, Texas. According to Dr. 
Stoudemire, Dr. Winkler has built “a community of strong connections and deep roots” at UT 
Austin. Dr. Winkler believed that Austin would become the next biotech hub like Boston or the 
Bay Area. He is not far from the truth as out of the four major cities in Texas—Houston, San 
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Antonio, Dallas, and Austin—Austin is the fastest growing startup city with the largest amount 
of newly financed startup companies (Egan 3).  
 
Current Situation of Mirna and Limitations of the Case Study 
 As mentioned earlier, due to the unsuccessful Phase I clinical trials from the toxicity 
incurred in the patients using miRNA-34, the company had to halt and terminate its study. 
Despite the fact that Mirna had many advantages, such as adequate funding from various 
sources, resource capital from its parent company, and promising results from its animal, 
preclinical studies, it could not foresee the outcome in its Phase I clinical trial. Interviews with 
Dr. Stoudemire and Dr. Brown, both integral in the clinical trial study, expressed their surprise 
and disappointment in the study’s results. They stated that the human body is much too complex 
to be modeled by only a mouse. Unfortunately, this is currently the best technology available to 
prescreen products before applying them in human studies. Even with the best possible starting 
position for a biotechnology company, there could be potential setbacks when dealing with the 
human body in clinical trials. Perhaps future research and methodologies will harness the 
computational power of technology to better predict the many variable outcomes before 
beginning human trials.  
 Since Mirna put all of its resources and high hopes into their one product, miRNA-34, its 
failure to pass the clinical trials has left the company in a tight predicament. With no product to 
enter the market to generate revenue on the horizon, and the fact that the company has been 
operating in debt since its inception, the company is now seeking to do a reverse merger. In other 
words, Mirna is looking for another company with the resources to buy their company and 
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assume leadership (Stoudemire). Mirna hopes the new company will be willing to pool 
resources, go back to the drawing board, and continue to do research (Stoudemire).   
 The case study represents only one of the many other biotechnology companies and thus 
by no means represent the end result for every biotech startup. However, the selected company 
provides a potentially unfortunate reality for those working or hoping to work in the field. Even 
with enough resource capital, stellar preclinical data, and the necessary management and means 
to operate clinical trials, the results from the trials may not always reflect the positive data 
obtained during the preclinical phase.  
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Conclusion 
 After conducting a literature review on mitigating issues for biotechnology startups, the 
importance of securing funding, the understanding of FDA regulations, the ability to test and 
conduct clinical trials, and the advantages of utilizing local resources were reoccurring areas of 
importance from authors who have successfully started their own biotechnology companies or 
have large amounts of expertise in this area. These four areas, if managed properly, can 
substantially help prevent a biotechnology startup from getting into trouble early on. As 
presented in the case study on Mirna Therapeutics Inc., the company was able to successfully 
achieve early funding, use the local university and its parent company’s resources and 
workforce, contract with a CRO to conduct clinical trials, and successfully navigate Phase I 
clinical trials, albeit the trials themselves for the product was unsuccessful.  
 Despite Mirna’s early successes of their product in preclinical settings on animal models, 
it did not preclude the possibility of bad results in the human studies in the trial. Furthermore, 
even though Mirna did everything right when getting started, no one could have predicted how 
patients would react to their product, highlighting the need for clinical trials in the first place. 
Therefore, it is important to note the limitations in following the recommended proposals offered 
by Tsai, Clarke, Durai, Kirkpatrick, and others in these areas of importance when starting a 
biotechnology company—it cannot guarantee long-term success but will prevent early failure.  
 In the coming decades, perhaps future research could explore the possibility of using 
machine learning techniques and other computation methods to better predict the probability of 
success for a given drug in clinical trials before actually conducting them. This would allow 
biotech companies to conserve more manpower, capital, and other resources and use them on a 
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clinical trial for a drug with the highest probability of success. Further research in this area may 
increase the success rate of biotechnology startups. 
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